13 results
8-K
EX-99.1
ALKS
Alkermes plc
9 Apr 24
Regulation FD Disclosure
7:09am
, cross-over treatment in patients with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).
In the healthy volunteer phase
8-K
EX-99.1
ALKS
Alkermes plc
23 Oct 23
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
8:27am
treatment in patients with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).
In the healthy volunteer phase of the study
DEFA14A
ALKS
Alkermes plc
7 Jun 23
Additional proxy soliciting materials
5:28pm
understanding of diseases in the field of neuroscience Hundreds of Alkermes’ employees volunteer each year as part of the Company’s employee - founded ALKERMES … IN ACTION volunteer program Sustainability and Environmental Impact Implemented enterprise - wide Environmental, Health, Safety and Security risk
DEFC14A
fttq7
25 May 23
Proxy in contested solicitation
4:03pm
PRER14A
ecgkivy xsejhi2
19 May 23
Preliminary revised proxy
5:23pm
PREC14A
cedt2n
8 May 23
Preliminary proxy with contested solicitation
4:34pm
DEFC14A
dxbi1
6 Jun 22
Proxy in contested solicitation
5:29pm
PREC14A
fio1 1847
26 May 22
Preliminary proxy with contested solicitation
5:29pm
- Prev
- 1
- Next